Summary Amplification and expression of the mdrl gene encoding P-glycoprotein have been studied in H69/LX4 a multidrug resistant variant (MDR) of small cell lung cancer (SCLC) cell line NCI-H69. Recently a second independently derived MDR variant of this cell line designated H69/AR was found by others not to show amplification, rearrangement or over-expression of the mdrl gene. The present study reports that in marked contrast to H69/AR, H69/LX4 shows amplification and expression of the P-glycoprotein gene and raises the possibility that P-glycoprotein hyperexpression may be a clinically relevant component of MDR in some SCLC tumours.Resistance of tumours to multiple drugs is a major problem in cancer treatment. Studies using in vitro derived multidrugresistant (MDR) cell lines have shown that MDR is often associated with over-production of two groups of proteins: the P-glycoproteins (for review see which have drug-binding properties (Safa et al., 1986) al., 1982;Gros et al., 1986;Kartner et al., 1983;Robertson et al., 1984;Scotto et al., 1986;Shen et al., 1986b;Van der Bliek et al., 1986b).In an effort to elucidate mechanisms of MDR in human small cell lung cancer (SCLC), multidrug resistant variants (MDR) of human SCLC cell line NCI-H69, have recently been derived following cell culture in increasing doses of adriamycin (ADM) Mirksi et al., 1987). Surprisingly, the MDR variant H69/AR (Mirski et al., 1987) does not show amplification, rearrangement or overexpression of the P-glycoprotein gene (Trent et al., 1988) suggesting that other factors are responsible for the MDR phenotype in these cells. The present study investigates Pglycoprotein gene amplification and expression in H69/LX4 (Twentyman et al., 1986) a second, independently derived MDR variant of NCI-H69. We report that, in marked contrast to H69/AR cells, amplification and hyperexpression of P-glycoprotein gene occurs in this MDR cell line.
Materials and methods
Cell linesThe SCLC cell line NCI-H69 (kindly supplied by Drs Desmond Carney and Adi Gazdar of the NCI Navy Medical Oncology Branch, Bethesda, MD) was derived from a patient who had previously received multidrug therapy (including ADM).Full details of the in vitro derivation of the MDR variant of NCI-H69 are given elsewhere . Briefly, NCI-H69 parent (H69P) cells were initially exposed to 0.02 pgml-1 ADM and then transferred to 0.04pgml-1 ADM after 3 weeks. After a further 4 weeks, ADM was removed and when cell growth resumed, ADM was reintroduced at weekly increasing doses of 0.1, 0.2 and